Dr. Chevli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3085 Harlem Rd
Ste 200
Cheektowaga, NY 14225Phone+1 716-844-5000Fax+1 716-844-5050
Education & Training
University of Louisville School of MedicineResidency, Urology, 1991 - 1994- University of Louisville School of MedicineResidency, Surgery, 1989 - 1991
Saint Louis University School of MedicineClass of 1989
Certifications & Licensure
NY State Medical License 1994 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MEDENT EMR/EHR, Community Computer Service, Inc., 2012-2013
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 88 citationsUrinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.K. Kent Chevli, Michael Duff, Peter Walter, Changhong Yu, Brian Capuder
The Journal of Urology. 2014-06-01 - 16 citationsPrimary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2...K. Kent Chevli, Neal D. Shore, Andrew Trainer, Angela B. Smith, Daniel Saltzstein
The Journal of Urology. 2021-08-26 - 1 citationsOptilume drug-coated balloon for anterior urethral stricture: 2-year results of the ROBUST III trial.Maia E VanDyke, Allen F Morey, Karl Coutinho, Kaiser J Robertson, Richard D'Anna
BJUI Compass. 2024-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
